EGFR and non-small cell lung carcinoma: The efficacy of these EGFR-TKIs in treating advanced NSCLC harboring EGFR mutation had been investigated in several large prospective clinical trials (Table 1) [18,19,20,21,22,23,24,25,26,27,30].